Abstract

Parkinson’s disease medication treatment planning is generally based on subjective data obtained through clinical, physician-patient interactions. The Personal KinetiGraph™ (PKG) and similar wearable sensors have shown promise in enabling objective, continuous remote health monitoring for Parkinson’s patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to cluster patients based on levodopa regimens and response. The resulting clusters are then used to enhance treatment planning by providing improved initial treatment estimates to supplement a physician’s initial assessment. We apply k-means clustering to a dataset of within-subject Parkinson’s medication changes—clinically assessed by the MDS-Unified Parkinson’s Disease Rating Scale-III (MDS-UPDRS-III) and the PKG sensor for movement staging. A random forest classification model was then used to predict patients’ cluster allocation based on their respective demographic information, MDS-UPDRS-III scores, and PKG time-series data. Clinically relevant clusters were partitioned by levodopa dose, medication administration frequency, and total levodopa equivalent daily dose—with the PKG providing similar symptomatic assessments to physician MDS-UPDRS-III scores. A random forest classifier trained on demographic information, MDS-UPDRS-III scores, and PKG time-series data was able to accurately classify subjects of the two most demographically similar clusters with an accuracy of 86.9%, an F1 score of 90.7%, and an AUC of 0.871. A model that relied solely on demographic information and PKG time-series data provided the next best performance with an accuracy of 83.8%, an F1 score of 88.5%, and an AUC of 0.831, hence further enabling fully remote assessments. These computational methods demonstrate the feasibility of using sensor-based data to cluster patients based on their medication responses with further potential to assist with medication recommendations.

Highlights

  • We examine patients’ demographic information under each clustering condition to identify statistically significant differences between optimized regimens to determine if demographic information alone may uniquely identify an optimized cluster

  • We examine the role of demographic information, MDS-Unified Parkinson’s disease Rating Scale (UPDRS)-III scores, and Personal KinetiGraphTM (PKG) time-series data in predicting the cluster allocation of patients

  • The PKG reports consisted of time-series data; dyskinesia and bradykinesia scores assessed every two minutes averaged over six days, along with medication administration times

Read more

Summary

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder resulting from the loss of dopaminergic neurons It is characterized by four cardinal motor symptoms: Bradykinesia (slowing of movement), muscle rigidity, tremor, and postural instability/gait disorder. Racial minorities, and rural communities have less access to care and lower quality of specialist care [7], causing delays in diagnosis and higher long-term disability [9,10]. It is further expected with the increasing number of PD patients, these inequities to the quality of care will become more prevalent [3]. These clinic visits are critical to improving an individual’s treatment planning and represent a potential bottleneck in the quality of patients’ care

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call